Table 5.
Variable | 30-day microbiological eradication | P value | |
---|---|---|---|
Success (n = 93) | Failure (n = 71) | ||
Age, years | 64.4 ± 16.7 | 66.7 ± 12.2 | 0.328 |
Sex (female) | 65 (69.9) | 40 (56.3) | 0.073 |
TBW, kg | 64.8 ± 14.0 | 64.5 ± 12.9 | 0.887 |
Primary site of infection | |||
Primary bloodstream infection | 13 (14.0) | 9 (12.7) | 0.808 |
Respiratory infection | 50 (53.8) | 42 (59.2) | 0.491 |
Abdominal infection | 14 (15.1) | 15 (21.1) | 0.312 |
Urinary tract infection | 11 (11.8) | 4 (5.6) | 0.173 |
Other infections | 5 (5.4) | 1 (1.4) | 0.236 |
Sepsis | 37 (39.8) | 22 (31.0) | 0.245 |
Polymicrobial infection | 13 (14.0) | 12 (16.9) | 0.606 |
APACHE II score (antimicrobial treatment onset) | 16 (14–19) | 17 (14–19) | 0.975 |
CrCl, mL/min | 67.0 (41.1–110.5) | 61.5 (41.0–121.5) | 0.828 |
CRRT | 15 (16.1) | 17 (23.9) | 0.194 |
ECMO | 1 (1.1) | 1 (1.4) | 1.000 |
Length of ICU stay before starting antimicrobial therapy, days | 30 (15–61.5) | 33 (20–50) | 0.960 |
Vasoactive drugs | 49 (52.7) | 39 (54.9) | 0.775 |
Mechanical ventilation | 59 (63.4) | 46 (64.8) | 0.859 |
Comorbidities | |||
Cardiovascular disease | 40 (43.0) | 44 (62.0) | 0.016 |
Respiratory disease | 43 (46.2) | 31 (43.7) | 0.743 |
Central nervous system disease | 21 (22.6) | 17 (23.9) | 0.838 |
Autoimmune disease | 7 (7.5) | 8 (11.3) | 0.410 |
Liver disease | 24 (25.8) | 20 (28.2) | 0.735 |
Renal insufficiency | 29 (31.2) | 23 (32.4) | 0.869 |
Diabetes | 26 (28.0) | 13 (18.3) | 0.150 |
Organ transplantation | 9 (9.7) | 6 (8.5) | 0.787 |
Neoplasia | 25 (26.9) | 10 (14.1) | 0.047 |
CCI score | 5 (3–6) | 4 (3–6) | 0.860 |
Antimicrobial treatment duration (> 7 days) | 83 (89.2) | 39 (54.9) | < 0.001 |
CAZ/AVI-based therapeutic regimens | 66 (71.0) | 16 (22.5) | < 0.001 |
Antimicrobial combination therapy | 63 (67.7) | 46 (64.8) | 0.691 |
All data are exhibited as number (%), mean ± SD, or median (interquartile range)